Market capitalization | $1.41b |
Enterprise Value | $1.03b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 16.80 |
P/S ratio (TTM) P/S ratio | 23.09 |
P/B ratio (TTM) P/B ratio | 3.73 |
Revenue growth (TTM) Revenue growth | 11.90% |
Revenue (TTM) Revenue | $61.10m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
8 Analysts have issued a Ocular Therapeutix Inc forecast:
8 Analysts have issued a Ocular Therapeutix Inc forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -44 -44 |
112%
112%
|
|
Depreciation and Amortization | 0.96 0.96 |
48%
48%
|
|
Stock Compensation | 11 11 |
156%
156%
|
|
Operating Cash Flow | -25 -25 |
24%
24%
|
|
Investments | 0.74 0.74 |
63%
63%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -26 -26 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Pravin Dugel |
Employees | 267 |
Founded | 2006 |
Website | www.ocutx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.